Newly FDA-approved Anticancer Agents: August 1, 2022-July 31, 2023 (Extended Table) TYPE OF TREATMENT GENERIC NAME WHAT IS IT? APPROVED FOR? CLINICAL TRIAL(S) FORMULATION Surgery, Chemotherapy, Radiotherapy flotufolastat fluorine-18 Imaging agent Certain type of prostate cancer NCT04186819, NCT04186845 IV pafolacianine* Imaging agent Certain type of lung cancer NCT04241315 IV Molecularly Targeted Therapy adagrasib§ Cell-signaling inhibitor Certain type of lung cancer NCT03785249 Tablet/Capsule fam-trastuzumab deruxtecan-nxki§ Antibody–drug conjugate Certain type of lung cancer* NCT04644237 IV selpercatinib Cell-signaling inhibitor Solid tumors carrying certain type of genetic mutation* NCT03157128 Tablet/Capsule mirvetuximab soravtansine-gynx§ Antibody–drug conjugate Certain type of ovarian cancer NCT04296890 IV elacestrant Antihormone Certain type of breast cancer NCT03778931 Tablet/Capsule futibatinib Cell-signaling inhibitor Certain type of bile duct cancer NCT02052778 Tablet/Capsule dabrafenib + trametinib Cell-signaling inhibitors Certain type of glioma* NCT02684058 Tablet/Capsule tucatinib + trastuzumab Cell-signaling inhibitors Certain type of colorectal cancer* NCT03043313 Tablet/IV olutasidenib§ Epigenome modifying agent Certain type of leukemia NCT02719574 Tablet/Capsule quizartinib§ Cell-signaling inhibitor Certain type of leukemia NCT02668653 Tablet/Capsule pemigatinib Cell-signaling inhibitor Certain types of blood cancer* NCT03011372 Tablet/Capsule pirtobrutinib Cell-signaling inhibitor Certain types of lymphoma NCT03740529 Tablet/Capsule zanubrutinib Cell-signaling inhibitor Certain types of lymphoma* NCT03336333, NCT03734016 Tablet/Capsule talazoparib DNA repair inhibitor Certain type of prostate cancer* NCT03395197 Tablet/Capsule Immunotherapy tremelimumab + durvalumab Immune checkpoint inhibitors Certain type of liver and lung cancers NCT03164616, NCT03298451 IV retifanlimab-dlwr Immune checkpoint inhibitor Certain type of skin cancer NCT03599713 IV durvalumab Immune checkpoint inhibitor Certain type of gallbladder cancer* NCT03875235 IV atezolizumab Immune checkpoint inhibitor Alverloar soft part sarcoma* NCT03141684 IV nadofaragene firadenovec-vncg Gene therapy Certain type of bladder cancer NCT02773849 IV teclistamab-cqyv Bispecific antibody Multiple myeloma NCT03145181, NCT04557098 IV mosunetuzumabaxgb Bispecific antibody Certain type of lymphoma NCT02500407 IV epcoritamab-bysp Bispecific antibody Certain type of lymphoma NCT03625037 IV glofitamab-gxbm Bispecific antibody Certain type of lymphoma NCT03075696 IV *New cancer type approved 2022-2023 §Requires a companion diagnostic IV, Intravenous SUPPLEMENTAL TABLE 2 AACR Cancer Progress Report 2023 Appendix 192
RkJQdWJsaXNoZXIy NTkzMzk=